- 8Sep, 2025
Antimicrobial resistance (AMR) has quickly become one of the most pressing health and economic challenges of our time, and it's creating an inflection point for biotech innovation and investment. With at least 1.27 million deaths attributed to AMR annually, the cost of inaction is clear. Beyond a moral obligation, investment in AMR is also a smart economic decision, and investors have begun disrupting the biotech market by supporting the momentum of the novel AMR solution pipeline.
The prospective bill, the Pasteur Act, is one potential strategy to help in these areas, and incentivize pharmaceutical companies to develop these essential therapies. This article was originally published on contagionlive.com.
This article was originally published in Genetic Engineering & Biotechnology News under the title of The Antimicrobial Resistance Crisis Eradicating a Global Health Threat
Reversing the Rapid Rise of Antibiotic Resistance. Greg Mario joins David E. Williams to discuss the real and potentially imminent dangers of antibiotic-resistant infections and the new technologies being developed to combat this growing threat.
- 12Nov, 2024
Antimicrobial resistance (AMR) is not a new phenomenon; it has been a persistent challenge since the discovery of antibiotics. TAXIS Pharmaceuticals is at the forefront of addressing antimicrobial resistance, developing innovative antimicrobial solutions.
- 24Oct, 2024
Startup Revolution: Greg Mario of TAXIS Pharmaceuticals On How Their Emerging Startup is Changing the Game
- 7Nov, 2024
On July 25, House Budget Committee bipartisan roundtable entitled, “Threats to Modern Medicine: Examining the Budgetary Effects of Antimicrobial Resistance (AMR) and the Broken Antibiotic Development Pipeline.”
Frank Carlo Pasqualone, MBA
Joe DePinto, MBA
Gregory G. Mario, MBA, President and CEO